Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Samrat Pharmachem Ltd (530125)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 530125 NSE: Pharmaceuticals & Drugs | Small Cap | Samrat Pharmachem Share Price
₹225.50 -0.45 (-0.20%)
As on 23-Sep'26 12:56
Samrat Pharmachem Ltd (530125)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 530125 NSE: Pharmaceuticals & Drugs | Small Cap | Samrat Pharmachem Share Price
₹225.50 -0.45 (-0.20%)
As on 23-Sep'26 12:56
Key Metrics
Valuation Multiples
Market Cap
₹70 Cr.
Current Price
₹225.5
52-Week Low / High
₹190 / 323
TTM EPS
-
TTM Sales
-
Book Value per Share
-
P/E Ratio
Industry PE
54.8
Price to Book (P/B)
Price to Sales (P/S)
EV/EBITDA
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
%
Return on Capital Employed (ROCE)
%
Return on Assets (ROA)
%
Operating Profit Margin
0%
Net Profit Margin
-%
Gross Profit Margin
0%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
1.52%
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
49.09%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
-
Equity
₹3.1 Cr.
Face Value
₹10
All Time Low / High
₹0.95 / 1250.00
Check Before You Invest
M-Cap below 100cr DeciZen not available
Is Samrat Pharmachem Ltd a good quality company?
Samrat Pharmachem Ltd is a quality company, based on a multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Samrat Pharmachem Ltd performance compare with that of its Peers?
Revenue growth of Samrat Pharmachem Ltd vs industry peers?
Samrat Pharmachem Ltd revenue CAGR is %, compared to the industry median CAGR of 0%, indicating stable growth and maintaining its market share.
Promoter shareholding and pledge status of Samrat Pharmachem Ltd?
Promoters hold 49.09% of the Samrat Pharmachem Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Samrat Pharmachem Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 19.5% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Samrat Pharmachem Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Value Creation ⓘ
| Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 5.3% | 16.4% | 23.1% | 11.8% | 22.4% | 23.9% | 52.3% | 34.9% | 4.1% | 13.6% | - |
| Value Creation Index ⓘ | -0.6 | 0.2 | 0.7 | -0.2 | 0.6 | 0.7 | 2.7 | 1.5 | -0.7 | 0.0 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 63.2 | 72.8 | 92.9 | 111 | 137 | 179 | 222 | 311 | 282 | 286 | 294 |
| Sales YoY Gr. | - | 15.1% | 27.8% | 19.6% | 23.7% | 30.2% | 23.9% | 40.1% | -9.4% | 1.5% | - |
| Adj EPS ⓘ | 1 | 5.7 | 10.4 | 5 | 13.7 | 17.3 | 55.5 | 53.4 | 4.7 | 22.2 | -7.2 |
| YoY Gr. | - | 494.7% | 84.3% | -52.3% | 176.5% | 25.9% | 220.6% | -3.7% | -91.3% | 377% | - |
| BVPS (₹) ⓘ | 44.5 | 49.6 | 60 | 65 | 78.7 | 95.9 | 151.5 | 204.4 | 210.4 | 232.4 | 223.5 |
| Adj Net Profit ⓘ | 0.3 | 1.7 | 3.2 | 1.5 | 4.3 | 5.3 | 17.1 | 16.5 | 1.4 | 6.9 | -2 |
| Cash Flow from Ops. ⓘ | -0.4 | -3.2 | 0.1 | 2.4 | -1.3 | 4.8 | 17.5 | -9.4 | 9.4 | -10.1 | - |
| Debt/CF from Ops. ⓘ | -15.4 | -2.2 | 71.9 | 2.8 | -7.1 | 1.8 | 0.4 | -2 | 0.9 | -1 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 18.3% | 15.8% | 8.8% | 1.5% | ||||
| Adj EPS ⓘ | 41.9% | 10.1% | -26.3% | 377% | ||||
| BVPSⓘ | 20.2% | 24.2% | 15.3% | 10.5% | ||||
| Share Price | 19.4% | 1% | -17.8% | -29.2% | ||||
Key Financial Parameters ⓘ
| Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 2.2 | 12 | 19 | 8 | 19.1 | 19.8 | 44.8 | 30 | 2.2 | 10 | -3.1 |
| Op. Profit Mgn % ⓘ | 1.9 | 5.1 | 6.4 | 2.9 | 4.8 | 4.8 | 10.9 | 7.7 | 0.9 | 3.6 | -0.5 |
| Net Profit Mgn % ⓘ | 0.5 | 2.4 | 3.5 | 1.4 | 3.1 | 3 | 7.7 | 5.3 | 0.5 | 2.4 | -0.8 |
| Debt to Equity ⓘ | 0.4 | 0.5 | 0.5 | 0.3 | 0.4 | 0.3 | 0.2 | 0.3 | 0.1 | 0.1 | - |
| Working Cap Days ⓘ | 103 | 116 | 98 | 89 | 93 | 84 | 87 | 89 | 123 | 131 | 64 |
| Cash Conv. Cycle ⓘ | 23 | 33 | 46 | 45 | 40 | 37 | 45 | 48 | 60 | 61 | 30 |
Valuation of Samrat Pharmachem - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
No data found!
No data found!
No data found!
No data found!
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Samrat Pharmachem Ltd FAQs
The current trading price of Samrat Pharmachem on 23-Sep-2026 12:56 is ₹225.5.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 22-Sep-2026 the market cap of Samrat Pharmachem stood at ₹69.81 Cr
The latest P/E ratio of Samrat Pharmachem as of 22-Sep-2026 is 0.00.
The latest P/B ratio of Samrat Pharmachem as of 22-Sep-2026 is 1.01.
The 52-week high of Samrat Pharmachem is ₹323.0 and the 52-week low is ₹190.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Samrat Pharmachem is ₹294 ( Cr.) .
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Samrat Pharmachem Ltd is a below average quality company.
The key valuation ratios of Samrat Pharmachem Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Samrat Pharmachem Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
About Samrat Pharmachem Ltd
Samrat Pharmachem was incorporated on June 16, 1992, at Ankleshwar in Gujarat. It was promoted by Lalit Mehta & Rajesh Mehta. The company is currently manufacturing iodine salts & bromine salts. The finished products produced by the company are used in various industries like Pharmaceuticals, Chemicals, Food, Fertilizer, Salt, etc. The products of the company are well received in Indian & foreign markets. The company is a public limited company & its shares are listed & traded on the Bombay Stock Exchange & other bourses of India. The company is presently employing 30 people for its operations at Ankleshwar & Mumbai.
The company’s manufacturing unit & test laboratory is situated in Ankleshwar. The factory is spread in an area of 3645 sq. mtrs. & has a constructed area of 20000 sq. ft. Technical innovation is their core strength. If anything is possible chemically, they strain their nerves to make it a reality. Research & Development is multi faceted focusing both on product & process development. Their commitment to keep the atmosphere beautiful & pure inspires them for further improvement in the process techniques.
The company is having a modern & well equipped quality control laboratory manned by experienced professionals who have set high standards for testing & approval. Starting with the raw materials, the intermediate stages & right upto the final stage, the products are continuously monitored for quality. The company's products & laboratory is approved by the Food & Drug Administration, Gandhinagar, Gujarat.
Samrat is well equipped to discharge its function round the year without any breakdown under adverse conditions. The company has fully computerized, centrally located office in the heart of Mumbai. Excellent documentation & personal attention to all national & international order ensures smooth & flawless logistical services. The company has well trained staff to meet any contingencies. Safe, convenient & tamper proof packaging ensures easy handling & reliability.The company is heading towards being accredited ISO 9000 & ISO 14000 Certification shortly.
The company is heading towards ERP implementation, which will integrate all the activities of the company on the internet thereby giving speedy information & reports.
Product range of the company includes:
Samrat has a major chunk of the business in Iodine & Bromine Salts. The company's customers include several multinational companies in India & Abroad. The company is exporting a part of its products to USA, Europe, Japan etc.
- Calcium Iodate Monohydrate
- Copper Iodide
- Hydriodic Acid 47%
- Hydriodic Acid 57%
- Iodine
- Iodine Monochloride
- Iodoethane (Ethyl iodide)
- Iodomethane (Methyl iodide)
- Potassium Bromide
- Potassium Iodate
- Potassium Iodide
- Potassium Metaperiodate
- Sodium Iodate
- Sodium Iodide
- Sodium Metaperiodate
- Trimethyl Sulfoxoniumiodide
Achievements/ recognition :
- The company's products & laboratory is approved by the Food & Drug Administration, Gandhinagar, Gujarat.
You have 47 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
